Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 183 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Interventions
CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Results available

Islet Transplantation Using Abatacept

NCT00276250
Conditions
Type 1 Diabetes Mellitus
Interventions
Efalizumab, Abatacept, Belatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Conditions
Metabolic Diseases
Interventions
human hepatocyte transplantation, Preparative Radiation Therapy
Drug · Radiation
Lead sponsor
Ira Fox
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
POTS - Postural Orthostatic Tachycardia Syndrome
Interventions
Questionnaires to be competed, Provide list of medication and lifetime events, Use phone App to record new life events, Will wear an activity monitor, Periodic 24-hour urine sodium check, A fMRI scan, A bedside tilt test will be performed, IV placed to collect blood samples, Stool Sample
Behavioral · Device · Other + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Unresectable Liver-limited Colorectal Metastases
Interventions
Liver transplant
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
1
States / cities
New York, New York
Conditions
Congenital Heart Disease, Congenital Heart Defect, Congenital Heart Malformations
Interventions
Nitric Oxide (NO) 20 part per million (ppm), Standard of care cardiopulmonary bypass
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 1 Year
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Sepsis, Shock, Septic
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Recruiting Not applicable Interventional

Preschool Hearing Screening

NCT06058767
Conditions
Hearing Loss, Hearing Disorders in Children, Hearing Loss, Sensorineural, Hearing Loss, Conductive, Hearing Loss, Unilateral, Hearing Loss, Noise-Induced, Hearing Loss, Mixed, Hearing Loss, Bilateral
Interventions
Otoacoustic Emissions Testing, Pure Tone Audiometry
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 6 Years
Enrollment
13,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Transplanted Organ Rejection
Interventions
FCR001
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more
Withdrawn Not applicable Interventional

MRI Adaptive Replanning Using ViewRay

NCT02950792
Conditions
Non-Small Cell Lung Cancer
Interventions
ViewRay MRI, Stereotactic Body Radiation Therapy Boost
Device · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
House Calls, Web-Based Patient-Centered Decision Support Intervention
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Organ Preservation
Interventions
Sub-Normothermic Machine Preservation and Assessment
Other
Lead sponsor
34 Lives, PBC
Industry
Eligibility
16 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more
Conditions
Head and Neck Cancer
Interventions
Temporally Feathered Radiation Therapy (TFRT)
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
Interventions
MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Completed Not applicable Interventional Results available

Surgery With or Without Adjuvant Stereotactic Body Radiotherapy

NCT02516969
Conditions
Head and Neck Cancer
Interventions
Stereotactic Body Radiotherapy
Radiation
Lead sponsor
David A. Clump, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Diabetes Mellitus, Type 1
Interventions
Artificial Pancreas
Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Years to 74 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more
Conditions
Kidney Transplantation, Delayed Graft Function
Interventions
CellCept
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
radiation therapy treatment planning/simulation, intensity-modulated radiation therapy, image-guided radiation therapy, magnetic resonance imaging, computed tomography
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
SARS-CoV-2
Interventions
mRNA-1273
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more
Conditions
Islet Cell Transplantation, Type 1 Diabetes
Interventions
Islet cell transplantation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Sickling Disorder Due to Hemoglobin S
Interventions
131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging
Drug · Radiation · Procedure
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Protocolized Care for Early Septic Shock

NCT00510835
Conditions
Sepsis, Severe Sepsis, Septic Shock
Interventions
Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more